Guidelines of care for the management of cutaneous squamous cell carcinoma
Abstract
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of human cancer and has an increasing annual incidence. Although most cSCC is cured with office-based therapy, advanced cSCC poses a significant risk for morbidity, impact on quality of life, and death. This document provides evidence-based recommendations for the management of patients with cSCC. Topics addressed include biopsy techniques and histopathologic assessment, tumor staging, surgical and nonsurgical management, follow-up and prevention of recurrence, and management of advanced disease. The primary focus of these recommendations is on evaluation and management of primary cSCC and localized disease, but where relevant, applicability to recurrent cSCC is noted, as is general information on the management of patients with metastatic disease.
MeSH terms
Funding
- Amgen
- Pfizer
- Sanofi
- Massachusetts General Hospital
- Celgene
- Regeneron Pharmaceuticals
- Exelixis
- DUSA Pharmaceuticals
- Valeant Pharmaceuticals International
- Castle Biosciences
- Astellas Pharma
- Genentech
How this paper connects to the literature. Drag to explore, click any node to open that paper.
